Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study
Hepatology · 2023-02 · 77 (2) · 489-500
DOI: 10.1002/hep.32737 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Hepatology, online erschienen am 17.10.2022. Verfasst von Marina Serper und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology , Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania , USA. Hauptthemen laut MEDLINE: Viremia, Hepatitis C. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, CSRD VA.
Abstract (Originalsprache)
Background and Aims: Little is known about the effectiveness of nonselective beta blockers (NSBBs) in preventing hepatic decompensation in routine clinical settings. We investigated whether NSBBs are associated with hepatic decompensation or liver‐related mortality in a national cohort of veterans with Child‐Turcotte‐Pugh (CTP) A cirrhosis with no prior decompensations. Approach and Results: In an active comparator, new user (ACNU) design, we created a cohort of new users of carvedilol ( n = 123) versus new users of selective beta blockers (SBBs) ( n = 561) and followed patients for up to 3 years. An inverse probability treatment weighting (IPTW) approach balanced demographic and clinical confounders. The primary analysis simulated intention‐to‐treat (“pseudo‐ITT”) with IPTW‐adjusted Cox models; secondary analyses were pseudo‐as‐treated, and both were adjusted for baseline and time‐updating drug confounders. Subgroup analyses evaluated NSBB effects by HCV viremia status, CTP class, platelet count, alcohol‐associated liver disease (ALD) etiology, and age. In pseudo‐ITT analyses of carvedilol versus SBBs, carvedilol was associated with a lower hazard of any hepatic decompensation (HR 0.59, 95% CI 0.42–0.83) and the composite outcome of hepatic decompensation/liver‐related mortality (HR 0.56, 95% CI 0.41–0.76). Results were similar in pseudo‐as‐treated analyses (hepatic decompensation: HR 0.55, 95% CI 0.33–0.94; composite outcome: HR 0.62, 95% 0.38–1.01). In subgroup analyses, carvedilol was associated with lower hazard of primary outcomes in the absence of HCV viremia, higher CTP class and platelet count, younger age, and ALD etiology. Conclusions: There is an ongoing need to noninvasively identify patients who may benefit from NSBBs for the prevention of hepatic decompensation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology , Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania , USA.
- Department of Medicine , Corporal Michael J. Crescenz VA Medical Center , Philadelphia , Pennsylvania , USA.
- Leonard David Institute of Health Economics , University of Pennsylvania Perelman School of Medicine , Philadelphia , Pennsylvania , USA.
- Division of Digestive Diseases , Yale University School of Medicine , New Haven , Connecticut , USA.
- VA Connecticut Healthcare System , West Haven , Connecticut , USA.
- Division of Gastroenterology and Hepatology , University of Michigan , Ann Arbor , Virginia , USA.
ORCID-Profile: Marina Serper
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- CSRD VA
- NCATS NIH HHS
- NCI NIH HHS
- NIA NIH HHS
Zitieren
APA
Serper, M., Kaplan, D. E., Taddei, T. H., Tapper, E. B., Cohen, J. B., & Mahmud, N. (2023). Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology, 77(2), 489-500. https://doi.org/10.1002/hep.32737
Vancouver
Serper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology. 2023;77(2):489-500. doi:10.1002/hep.32737
BibTeX
@article{Serper2023,
author = {Serper, Marina and Kaplan, David E and Taddei, Tamar H and Tapper, Elliot B and Cohen, Jordana B and Mahmud, Nadim},
title = {Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study},
journal = {Hepatology},
year = {2023},
volume = {77},
number = {2},
pages = {489--500},
doi = {10.1002/hep.32737}
}
EUVIMED